Bris­tol My­ers lines up a date with the FDA to ex­pand the foot­print of its $13B heart drug

In April, Bris­tol My­ers Squibb won ap­proval for mava­camten, now mar­ket­ed as Camzyos, to im­prove symp­toms of ob­struc­tive hy­per­trophic car­diomy­opa­thy (oHCM), a con­di­tion in which …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER